Homburger advised Zürcher Kantonalbank on the issuance of EUR 500 m Bail-in Bonds. The bonds, including the newly placed EUR 500 m 3.622% 6NC5 Bail-in Bonds, have been designed and issued on the basis of a legal
Tags :Benjamin Leisinger
Space Exploration Technologies Corp. (SpaceX) concluded a USD 75 billion initial public offering. In connection with the operation, Homburger advised SpaceX, while Lenz & Staehelin represented the underwriters — a syndicate led by Goldman Sachs & Co.,
Homburger advised Siegfried Holding on the issuance of its CHF 200 million 1.350% bonds. UBS Investment Bank and Zürcher Kantonalbank acted as joint lead managers. The bonds will be issued on June 15, 2026, and will be listed
Homburger advised Raiffeisen Schweiz Genossenschaft on the issuance of its inaugural CHF 200 million 1.44% digital bail-in bond due 2033, to be traded on the SIX Swiss Exchange.
Homburger acted as counsel to Zürcher Kantonalbank on the issuance of EUR 500 million 3.080 per cent Fixed Rate Bonds due May 2029, with BNP Paribas, Commerzbank, UBS AG London Branch, and Zürcher Kantonalbank serving as
Homburger advised Novartis Finance on the issuance of EUR 600 m 3.100 per cent. fixed rate notes due January 13, 2032, EUR 600 m 3.500 per cent. fixed rate notes due May 13, 2035 and EUR 500 m 4.000 per cent. fixed rate notes due
Homburger advised the Joint Lead Managers on the issuance of EUR 500 million 3.925% Guaranteed Bonds by EFG International Finance (Luxembourg), guaranteed by EFG International AG and governed by Swiss law.
Homburger advises Mondelēz International, as the company placed bonds in Switzerland in the aggregate amount of CHF 850 m. The placement The CHF offering included CHF 325 m aggregate principal amount of 0.9575% senior notes due 2029, CHF 245
Homburger advised Raiffeisen Schweiz Genossenschaft on the issuance of CHF 465 m state treasury notes by the State of North Rhine-Westphalia under its debt issuance programme. The notes in question are governed by German law, and
Swiss healthcare company Novartis, acting through one of its wholly-owned indirect subsidiaries, completed the acquisition of RNA therapeutics specialist Avidity Biosciences, for a total value of approximately USD 12 bn. In connection with the deal, Homburger
